Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/0004—Oxidoreductases (1.)
  • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
  • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
  • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
  • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
  • C07K14/245—Escherichia (G)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
  • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/10—Transferases (2.)
  • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
  • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
  • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/90—Isomerases (5.)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
  • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
  • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
  • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide

Definitions

• TECHNICAL FIELD This invention is in the field of drug screening and drug discovery. More particularly, techniques of microbial genetics are utilized to provide methods and compositions for identifying targets and screening candidate therapeutics.
• Screening for inhibitors of a particular enzyme has been accomplished by comparing the effect of a test compound on a strain that is defective for the enzyme with the effect of the test compound on a strain harboring a different mutation. See, for example, EP 644268.
• Other screening systems have been developed which depend on generating strains which express mutant proteins (e.g., temperature-sensitive proteins) and assessing their sensitivity to test compounds. See, for example, PCT Publication WO 96/23075.
• One object of the invention is to provide methods and compositions for identifying compounds which inhibit the growth or viability of an organism, regardless of whether the mechanism of action of the inhibitor and/or the function of the inhibitor's target is known.
• Another object of the invention is to provide compositions and methods for screening compounds using cells that are hypersusceptible to an inhibitor.
• An additional object of the invention is to provide methods for generating cells that are hypersusceptible to a known inhibitor, utilizing techniques of molecular genetics and recombinant DNA, in particular, techniques that permit regulated expression of a target gene, including underexpression, expression at normal levels, and overexpression.
• a further object of the invention is to provide compositions and methods for identifying essential genes and gene products of microorganisms, as well as genes and gene products that are involved in virulence and drug resistance.
• Yet another object of the invention is to provide methods and compositions for determining the mechanism of action of an inhibitor.
• a further object of the invention is to provide methods and compositions for controlled gene expression.
• An additional object is to provide methods and compositions that will allow expression of a particular target gene to be regulated at levels that are both lower and higher than those normally present in the cell.
• the invention provides cells in which the expression of a gene product involved in an essential function can be regulated.
• the invention provides cells in which the expression of a gene can be down-regulated to express the gene product below wild-type levels, as well as cells in which gene expression can be up-regulated to levels that are higher than wild-type.
• expression of a gene product at lower-than-normal levels will, in and of itself, result in an impairment or absence of growth which defines the gene product as being essential.
• environmental conditions such as, for example, temperature, pH, nutrient sources, ionic strength, presence of other organisms, infection and/or presence of a compound under which expression of a particular level of a given gene product is essential can be determined.
• the methods and compositions of the invention will allow expression of any gene in a cell to be independently regulated by external stimuli, such as nutrient concentration.
• external stimuli such as nutrient concentration.
• Genes whose expression can be down-regulated to a point at which levels of that particular gene product become limiting for growth or other important cell function (e.g., pathogenesis or resistance to antibiotics) can then be identified. Once such a gene has been identified, cells expressing that gene at any level between that which is limiting and any higher expression level can be challenged with a test compound.
• Compounds which exhibit higher potency against cells expressing lower levels of gene product are candidate inhibitors.
• the invention provides methods and compositions for the identification of compounds that affect essential cellular processes, by exposing to a test compound cells in which expression of a gene product that is involved in an essential cellular process is regulated to a lower-than-normal level.
• the invention provides methods and compositions for determining the target and mechanism of action of an inhibitor by exposing, to a test compound, cells in which expression of a gene product that is involved in an essential cellular process is regulated to a lower-than-normal level.
• the invention provides methods and compositions for determining the target and mechanism of action of an inhibitor by exposing, to a test compound, a library of cells in which expression of a variety of gene products that are involved essential cellular processes are regulated to lower-than- normal levels.
• the practice of the invention will allow identification of genes encoding drug targets, genes encoding essential cellular functions, genes encoding virulence factors, genes encoding antibiotic resistance factors, polypeptides or fragments thereof that serve as drug targets or virulence factors; polypeptides or fragments thereof that participate in essential cellular functions or antibiotic resistance; RNAs that serve as drug targets or virulence factors and RNAs that participate in essential cellular functions or antibiotic resistance.
• Cells in which expression of a gene product that is involved in an essential cellular process is regulated to a lower-than-normal level can be obtained through techniques of microbial genetics and molecular biology. For example, fusion of a heterologous regulatory element to an essential gene places that gene under the control of the heterologous regulatory element.
• the heterologous regulatory element may intrinsically provide lower expression levels than the essential gene's normal regulatory system, or the heterologous regulatory element may be capable of being down-regulated. In either case, expression of the essential gene at lower-than-normal levels is possible.
• the invention also provides methods and compositions for regulated gene expression, whereby expression is controlled over a range of levels ranging from underexpression through normal expression levels through overexpression.
• exemplary compositions include regulatable promoters, enhancers, operators and other transcriptional and/or translational control elements.
• Exemplary methods include methods for placing regulatable promoters, enhancers, operators and other transcriptional and/or translational control elements into operative linkage with a gene or coding sequence, and expression of such constructs in a cell, wherein expression is regulated by an inducer and/or repressor.
• Methods and compositions for regulated expression of a gene in a microorganism are also provided; wherein the methods utilize a construct comprising a gene, or a fragment thereof, in operative linkage with a regulatory element such as the E. coli P ⁇ BAD promoter or the P AGA promoter of S. pneumoniae.
• the methods comprise introducing the construct into a host cell, culturing the host cell in a growth medium and adjusting the concentration of one or more
• Modulator substances can be inducers and/or negative modulators (i.e., repressors) of the r regulatory element(s) present in the construct.
• compositions and methods for making a construct comprising a gene or a fragment thereof in operative linkage with a component of the r ⁇ /regulatory region of S. pneumoniae, are provided.
• Such constructs can be chromosomal or extrachromosomal.
• the invention will therefore be useful for drug screening, target identification, determining mechanisms of action of antibiotics, determining mechanisms of virulence and antibiotic resistance, and for other purposes as will be apparent to those of skill in the art.
• Figure 1 shows the nucleotide sequence of the S. pneumoniae Px and Pm regions. (SEQ ID NO: 1). The mutation in the repressor binding site of the Px promoter, converting a GGA sequence to GCG (mutant construction described in Example 6) is indicated on the bottom line of the figure.
• Figure 2 is a schematic diagram of the S. pneumoniae r ⁇ / ' gene cluster, including the two r ⁇ operons, with open reading frames (ORFs) represented by arrows. Locations of promoters is also indicated. Shown for comparison is a schematic diagram of ORFs in the msm region of S. mutans.
• Figure 3 shows the nucleotide sequence of the r ⁇ /region of S. pneumoniae strain VSPN3026 (SEQ ID NO. 2). The general location of the P AGA promoter is indicated by underlining.
• Figure 4 shows idealized results of an experiment in which the minimum inhibitory concentration of a compound is determined as a function of inducer concentration, in a cell in which target expression level is regulated by inducer concentration and the target is a single component which is inhibited by the compound.
• Figure 5 shows idealized results of an experiment in which the minimum inhibitory concentration of a compound is determined as a function of inducer
• FIG. 7 concentration, in a cell in which either 1) the target comprises multiple components and the compound interacts with a site defined by two or more of the components or 2) the compound interacts with multiple targets, and the level of one of the components (or targets) is regulated by inducer concentration.
• Figure 6 shows a scheme for replacement of wild type murA regulatory elements with an ara regulatory cassette.
• Figure 7 shows growth of a ⁇ BAD-mur fusion strain (E. coli VECO2055) as a function of arabinose concentration.
• Figure 8 shows the minimum inhibitory concentration of fosfomycin, as a function of arabinose concentration, for the P& ⁇ -mwrA fusion strain E. coli VECO2055, compared to wild-type.
• Figure 9 shows minimum inhibitory concentrations of fosfomycin, ciprofloxacin, and tetracycline for the E. coli V ⁇ A D-murA fusion strain VECO2055, expressed as a function of arabinose concentration.
• Figure 10 shows optical density measurements, at various times after inoculation, of cultures of VSPN3041 grown at different raffmose concentrations.
• Figure 11 shows optical density measurements of the growth of VSPN3041 on either sucrose or raffmose.
• Figure 12 shows the growth of VSPN3041 and the parent isogenic strain VSPN3026, at different raffmose concentrations. Growth was measured by optical density after 10 hours of culture.
• Figure 13 shows the susceptibility of VECO2065, an E. coli strain having a chromosomal BAD -df fusion, to VRC483, an inhibitor of the e/gene product. Susceptibility is presented as minimum inhibitory concentration (MIC) of VRC483 in ⁇ g/ml, as a function of inducer (arabinose) concentration. Also shown is the susceptibility of VECO2065 to fosfomycin and ciprofloxacin.
• MIC minimum inhibitory concentration
• Figure 14 shows the susceptibility of VECO2079, an E. coli strain having a chromosomal Ys AD -falA fusion, to trimethoprim, an inhibitor of X efolA gene product. Susceptibility is presented as minimum inhibitory concentration (MIC) of trimethoprim in ⁇ g/ml, as a function of inducer (arabinose) concentration. Also shown is the susceptibility of VECO2079 to fosfomycin and ciprofloxacin, and
• Figure 15 shows the susceptibility of VECO2083, an E. coli strain having a chromosomal V BAD -gyrB fusion, to novobiocin, an inhibitor of the gyrB gene product. Susceptibility is presented as minimum inhibitory concentration (MIC) of novobiocin in ⁇ g/ml, as a function of inducer (arabinose) concentration. Also shown is the susceptibility of VECO2083 to fosfomycin and ciprofloxacin.
• MIC minimum inhibitory concentration
• Figure 16 shows the susceptibility of VECO2068, an E. coli strain having a chromosomal P BAD -def fusion and a tolC deletion, to VRC483, an inhibitor of the e/gene product (indicated by the curve labeled VRC483).
• Susceptibility is presented as minimum inhibitory concentration (MIC) of VRC483 in ⁇ g/ml, as a function of inducer (arabinose) concentration.
• MIC minimum inhibitory concentration
• inducer arabinose
• FIG 17 shows the susceptibility of VSPN3044 to VRC483, an inhibitor of the e/gene product.
• VSPN3044 contains a PAGA-def transcriptional fusion, so that expression of the defge product is regulated by raffmose.
• Susceptibility is presented as minimum inhibitory concentration (MIC) of VRC483 in ⁇ g/ml, as a function of inducer (raffmose) concentration.
• MIC minimum inhibitory concentration
• raffmose induceraffmose
• Figure 18 shows the susceptibility of VECO2524 (V BAD -IPXC, AtolC) toL 159692, an antibacterial compound that targets the IpxC gene product.
• Minimum inhibitory concentration is shown as a function of arabinose concentration. Also shown are minimum inhibitory concentrations of linezolid and erythromycin as a function of arabinose concentration.
• the present invention provides methods and compositions useful for identification of compounds that affect an essential cellular process, compounds that interfere with mechanisms of resistance, and compounds that interfere with virulence factors; for identification of the target or targets of a compound that affects an essential cellular process, a mechanism of resistance or a virulence factor; for identification of a gene or genes encoding a target or targets of a compound that affects an essential cellular process, a mechanism of resistance or a virulence factor; and for identification of genes, RNAs and polypeptides involved in essential cellular processes, mechanisms of resistance or virulence. Identification is facilitated by controlled expression of a gene that is involved in an essential cellular process. Knowledge of the function of a gene or its product is not required, either to identify it as being involved in an essential cellular process, or to identify a compound which affects the gene product.
• compositions embodied by the invention will include microorganisms wherein the expression of an essential gene of the microorganism is regulated by fusion to a heterologous regulatory element.
• target genes and polypeptides whose expression is regulated by a heterologous regulatory element will often be those that are essential for viability of a microorganism, or responsible for its virulence or drug resistance.
• Microorganisms can be either prokaryotic or eukaryotic; and prokaryotes can be either Gram-positive or Gram-negative. Exemplary prokaryotes include, but are not limited to: Staphylococcus (e.g., S.
• aureus S. epidermidis
• Streptococcus e.g., S. pneumoniae, S. pyogenes, S. agalactiae
• Enterococcus E. faecalis, E.faecium
• Neisseria Branhamella, Listeria, Bacillus (e.g., B. subtilis), Corynbacterium, Erysipelothrix, Gardnerella, Nocardia, Mycobacterium, enterobacteriaceae, Escherichia (e.g., E. coli), Salmonella, Shigella, Yersinia, Enterobacter (e.g., E. cloacae), Klebsiella (e.g., K.
• pneumoniae K. oxytoca
• Citrobacter Serratia, Providencia, Proteus (e.g., P. mirabilis, P. vulga ⁇ s), Morganella (e.g., M. morganii), Edwardsiella, Erwinia, Vibrio, Aeromonas, Helicobacter (e.g., H pylori), Campylobacter, Eikenella, Pasteur ella, Pseudomonas (e.g., P.
• aeruginosa Burkholderia
• Stenotrophomonas Acinetobacter, Ralstonia, Alcaligenes, Moraxella, Legionella, Francisella, Brucella, Haemophilus (e.g., H. influenzae), Bordetella, Clostridium, Bacteroides, Porphyromonas, Prevotella, Fusobacterium, Borrelia, Chlamydia, Ricketsia, Ehrlichia and Bartonella.
• Exemplary eukaryotic microorganisms include, but are not limited to, yeasts and fungi, for example, Candida (e.g., C. albicans), Cryptococcus, Pneumocystis, Histoplasma, Blastomyces, Coccidioides, Aspergillus, Fusarium, Saccharomyces and Schizosaccharomyces.
• Candida e.g., C. albicans
• Cryptococcus e.g., C. albicans
• Pneumocystis e.g., Pneumocystis
• Histoplasma e.g., Blastomyces, Coccidioides
• Aspergillus Fusarium
• Saccharomyces and Schizosaccharomyces eukaryotic cells
• malignant eukaryotic cells such as plant cells, mammalian cells and human cells.
• malignant eukaryotic cells such as plant cells, mamm
• a therapeutic can comprise a compound, such as a drug, a composition comprising multiple compounds, or a physical treatment, such as radiation.
• the invention provides methods and compositions for identifying genes and/or gene products involved in essential cellular functions.
• An essential function for a particular cell will depend on the genotype of the cell and the cell's environment.
• essential cellular functions are those which are involved in replication, repair, recombination and transcription of genetic material; protein synthesis (translation), processing and transport; protein export; anabolic synthesis of cellular molecules; catabolism of cellular nutrients; synthesis of cell membranes and cell walls; lipid metabolism; protein metabolism; energy metabolism; cell division; cell shape; filamentation; regulation; DNA binding; RNA binding; efflux systems; transport systems; virulence or pathogenicity; and drug resistance.
• Protein metabolism can include protein modifications such as glycosylation, phosphorylation, acetylation and ubiquitination, to name but a few examples.
• Gene products that can be involved in essential cellular processes include, but are not limited to, topoisomerases, nucleases, recombinases, primases, helicases, DNA polymerases, RNA polymerases, histone modifying enzymes, kinases, phosphatases, acetylases, deacetylases, formylases, deformylases, chaperonins, ion transporters, cytoskeletal elements, colicins, cytochromes, ribosomal proteins, transfer RNAs, ribosomal RNAs, hydrolases, proteases, epimerases, rotamases, synthases, racemases, dehydrogenases, transferases, ligases, reductases, oxidases, transglycosylases, transpeptidases,
• an essential cellular process is any process which, when it occurs at a lower rate or to a lesser extent than normal, negatively influences the viability of the cell.
• Methods for determination of cell viability include, but are not limited to, vital staining, cell counting, either microscopically or by colony counting following serial dilution and plating of cell cultures, measurement of light scattering by cell cultures, fluorescence-activated cell sorting, incorporation of polynucleotide and/or polypeptide precursors, reporter gene expression, and measurement of cell weight and/or volume.
• the types of molecules that can participate in essential cellular processes can include nucleic acids, polypeptides and other cellular macromolecules.
• Nucleic acids will include, for example, DNA; regulatory RNA molecules, such as ribozymes and antisense RNA; transfer RNA and ribosomal RNA.
• Polypeptides can include, for example, structural proteins, enzymes, receptors, intracellular signaling molecules, and cellular adhesion molecules.
• the expression of a gene involved in an essential cellular function is regulated by fusion of the gene, or a fragment thereof, to a heterologous regulatory element.
• a heterologous regulatory element is one that is not normally associated with, and does not normally regulate, the gene which it regulates in the practice of the invention.
• Regulatory elements can comprise transcriptional, post-transcriptional, translational, and post-translational elements; as well as regulatory elements related to replication.
• transcriptional regulatory elements can include promoters, enhancers, operators, and elements that modulate the rate of transcription initiation, elongation and/or termination; post-transcriptional regulatory elements can include those influencing messenger stability, processing and transport; translational regulatory elements can include those which modulate the frequency of translation initiation and the rate of translational elongation; post-translational regulatory elements can include those which influence protein processing,
• stability and transport; and replication-associated regulatory elements can include those related to gene dosage.
• the heterologous regulatory element comprises a regulatable promoter.
• the regulatable promoter is the ⁇ r ⁇ BAD promoter, also known as VB AD - Regulation by V BAD has been the subject of extensive study and its regulatory properties are well- understood. See, for example, Sc leif (1992) Ann. Rev. Biochem. 61:199-223; Guzman et al (1995) J Bacteriology 177:4121-4130; and Gallegos et al. (1997) Microbiology and Molecular Biology Reviews 61:393-410.
• the V BAD promoter is regulated by the AraC protein, which has both positive and negative regulatory activities.
• AraC represses transcription from V BAD by binding to sites upstream of the V BAD transcription initiation site.
• Inducers such as L-arabinose interact with the AraC protein to form an activator of V BAD transcription that binds to different upstream sites to stimulate transcription.
• desirable features of the AvaC/V BAD regulatory system are the very low basal levels of transcription obtained in the absence of arabinose and the direct relationship between transcription from V BAD and the concentration of arabinose in the medium. See, for example, Guzman et al, supra.
• V BAD The activity of V BAD is directly proportional to the concentration of arabinose in the environment and, importantly, at low arabinose concentration, very low basal levels of expression are obtained.
• the V BAD promoter is also subject to regulation by catabolite repression, mediated by cyclic AMP and by the cyclic AMP receptor protein, also known as the catabolite repressor protein (CRP).
• CRP catabolite repressor protein
• further modulation of V BAD expression can be obtained by regulating the concentration of glucose (or other carbon source such as, for example, glucose-6-phosphate) in the environment, which modulates CRP activity within the cell.
• minimal expression of V BAD maximal repression
• V BAD 14 rapid induction of transcription from V BAD wherein the expression level is proportional to the arabinose concentration. Expression levels varying over a 1 ,000-fold range can be obtained, depending on the inducer concentration. See, for example, Guzman et al., supra.
• the V BAD promoter or any other promoter of the AraC/XylS family, from any prokaryotic or eukaryotic organism, can be used in the practice of the invention. See, for example, Gallegos et al, supra; de Vos et al. (1997) Curr. Opin. Biotechnol 8:547-553; and Kleerebezem et al. (1997) Mol. Microbiol. 24:895-904. Particularly preferred are the V BAD promoters of E. coli and S. typhimurium.
• malM/malX system of S. pneumoniae regulated by MalR.
• MalR is a repressor that controls the expression of the maltosaccharide regulon in S. pneumoniae and belongs to the LacI-GalR family of repressors.
• Two operons are regulated in opposite direction, malXCD (Px promoter) and malMP (Pm promoter), see Figure 1 (SEQ ID NO: 1). Stassi et al. (1982) Gene 20:359-366; and Nieto et ⁇ /. (1997) J. Biol. Chem. 272:30860-30865.
• a regulatory system that is useful in the practice of the invention is the r ⁇ /regulatory system of Streptococcus pneumoniae.
• Example 14 shows that the rafR gene product acts as a positive regulator of promoters such as P AGA , the promoter for the S. pneumoniae ⁇ -galactosidase gene.
• P AGA promoter for the S. pneumoniae ⁇ -galactosidase gene.
• fusion of a target gene to P AGA in a cell expressing rafR function, will allow raffinose- regulated expression of the target gene.
• Additional regulatory elements in the r /regulatory system include the promoter of the rafR gene, P ra f R , and the promoter of the rafE gene, P rq ⁇ .
• the P AGA promoter was discovered through a search of the S. pneumoniae genome sequence, disclosed at http://www.tigr.org. The sequence was searched
• the gene cluster contains two operons transcribed divergently: a regulatory operon encoding rafR and ra ⁇ , and a metabolic operon which encodes aga, rafE, rafF, rafG, gtfA and possibly rafH.
• the nucleotide sequence of the region of the r ⁇ gene cluster encompassing ra ⁇ , rafR, and aga, in S. pneumoniae strain VSPN3026 was determined. See Figure 3 (SEQ ID NO: 2).
• the ra ⁇ gene was determined to lie between the complements of nucleotide coordinates 1001-291 of this sequence, with the region encoding RafS protein lying between the complements of nucleotides 938-294.
• the rafR gene was determined to lie between the complements of nucleotides 1798-935, with the RafR coding region complementary to nucleotides 1795-938.
• the aga gene extended from nucleotides 1903-4065, with the coding region lying between 1903-4062.
• the S. pneumoniae r ⁇ gene cluster is organized into two domains.
• One domain includes the two regulatory ORFs rafR and ra ⁇ , and the other includes genes that are probably involved in uptake and catabolism, based on their
• r ⁇ gene cluster refers to the raf transcriptional units and their related regulatory genes, in particular the region of the S. pneumoniae genome comprising the rafR, ra ⁇ , aga, rafE, rafF, rafG, gtfA and rafH genes, as well as the intergenic regions associated with these genes.
• Intergenic regions refer to DNA sequences which do not encode protein, but which lie adjacent to protein-coding regions of DNA sequence. Intergenic regions will often contain regulatory sequences such as promoters and operators, although regulatory sequences can also be located in coding regions.
• rafR Directly upstream of rafR is a divergently-transcribed gene, aga, with sequence homology to S. mutans ⁇ -galactosidase. Construction of a strain with a mutation in the aga region, followed by ⁇ -galactosidase assay of the mutant strain, shows that the S. pneumoniae aga gene does indeed encode a polypeptide with ⁇ -galactosidase activity. See Example 14. Downstream of aga are additional genes encoding proteins homologous to the msm transport system, and a gene called gtfA, which is a homologue of S. mutans sucrose phosphorylase. Although it contains several homologous ORFs, the fact that the S. pneumoniae raf gene cluster contains two regulatory genes suggests that its regulation may be more complex than that of the msm gene cluster in S. mutans.
• the S. pneumoniae raf gene cluster contains at least two regulatory genes, rafR and ra ⁇ , an intergenic region, and at least five structural genes: aga, rafE, rafF, rafG and gtfA. See Figure 2. Sequences which regulate the expression of the regulatory and structural genes of the S. pneumoniae raf gene cluster are likely to be found in the intergenic region and within genes adjacent to the intergenic region.
• r ⁇ regulatory sequences include, for instance, promoter and operator sequences, such as the rafR promoter (P ra fld, the ⁇ -galactosidase promoter (PAGA) and the rafE promoter P r fE- Promoter sequences are those to which RNA polymerase binds to initiate transcription.
• Operator sequences are those to which regulatory proteins (such as, for example, activators and repressors) bind, thereby influencing the ability of RNA polymerase to bind to the promoter. In general, repressors inhibit binding of RNA polymerase, and activators facilitate binding (or relieve repressor-mediated inhibition).
• the invention provides sequences from the raf regulatory region, such as r ⁇ /promoter and operator sequences, for the regulated expression of coding sequences, which can include, for example, homologous and heterologous genes or gene fragments.
• a homologous gene is one that is normally found in association with the regulatory sequences in nature.
• a heterologous sequence is a sequence from S. pneumoniae or any other organism, that is not normally found in association with S. pneumoniae r ⁇ /regulatory sequences in nature.
• pneumoniae regulatory sequences include, but are not limited to, the rafR promoter (P ra fR), the ⁇ -galactosidase promoter (P AGA ), and the promoter of the rafE gene, P rq ⁇ -
• the rafR gene product acts as a positive regulator and the ra ⁇ gene product acts as a negative regulator of the ra/Operons.
• Growth of cells in the presence of raffmose induces expression of genes under the control of r ⁇ /regulatory sequences, while growth of cells on sugars other than raffmose inhibits expression of genes under the control of ra/regulatory sequences. Consequently, the methods and compositions provided by the invention allow for both overexpression and underexpression of a gene, mediated by rfl/regulatory sequences.
• the invention provides recombinant constructs for regulation of expression of a gene of interest.
• the recombinant constructs are
• a coding sequence in operative linkage with r ⁇ /regulatory region sequences, either by insertion of a coding sequence in proximity to a rfl/regulatory sequence, or by insertion of a rfl/regulatory sequence in proximity to coding sequence.
• the rfl/regulatory sequence will be upstream of the coding sequence when they are placed in operative linkage. Locations of restriction enzyme recognition sequences within the raf gene cluster, for use as insertion sites, can be easily determined by one of skill in the art from the nucleotide sequence of the raf gene cluster.
• various in vitro techniques can be used for insertion of a restriction enzyme recognition sequence at a particular site, or for insertion of heterologous sequences at a site that does not contain a restriction enzyme recognition sequence.
• Such methods include, but are not limited to, oligonucleotide-mediated heteroduplex formation for insertion of one or more restriction enzyme recognition sequences (see, for example, Zoller et al. (1982) Nucleic Acids Res. 10:6487-6500; Brennan et al (1990) Roux's Arch. Dev. Biol. 199:89-96; and Kunkel et al (1987) Meth. Enzymology 154:367-382) and PCR-mediated methods for insertion of longer sequences.
• Operative linkage refers to an arrangement of one or more regulatory sequences with one or more coding sequences, such that the regulatory sequence(s) is capable of exerting its regulatory effect on the coding sequence.
• a transcriptional regulatory sequence or a promoter is operably linked to a coding sequence if the transcriptional regulatory sequence or promoter promotes transcription of the coding sequence.
• an operator is considered operatively linked to a promoter or to a coding sequence if binding of a repressor to the operator inhibits initiation at the promoter so as to prevent or diminish expression of the coding sequence.
• An operably linked transcriptional regulatory sequence is generally joined in cis with the coding sequence, but it is not necessarily directly adjacent to it.
• Recombinant constructs comprising coding sequences in operative linkage with one or more rfl/regulatory region sequences can also comprise other types of
• sequence including, but not limited to, replication origins, selectable markers (including, but not limited to, those encoding antibiotic resistance), transcription termination sites, sequences specifying translation initiation and termination, sequences mediating mRNA processing and/or stability and multiple cloning sites.
• these additional sequences are functional in Gram- positive microorganism, such as, for example, Streptococci, Staphylococci, Enterococci, and Lactococci.
• Preferred species include, for example, S pneumoniae, S. pyogenes, S.
• Preferred non-streptococcal species in which these additional sequences are functional include, for example, enterococci such as E. faecalis, and E. faecium, and lactococci such as L. lactis. Methods for the construction of such recombinant constructs are well-known to those of skill in the art. See, for example, Sambrook et al, supra.
• selectable markers include those which facilitate positive selection, such as a sequence which encodes antibiotic resistance, and those which facilitate negative selection. Bochner et al. (1980) J. Bacteriol 143:926-933; and Gay et al. (1985) J. Bacteriol 164:918-921.
• Recombinant constructs can exist as freely-replicating extrachromosomal elements, such as plasmids or episomes, or can exist as chromosomal recombinants, such as would be achieved either by integration of a rfl/regulatory cassette into the chromosome of a microorganism adjacent to a gene of interest, or by insertion of a gene of interest into the chromosome adjacent to a rfl/regulatory sequence, for example.
• a coding sequence can encode a full-length gene product ( . e. , the length normally found in the wild-type cell) or any fragment of a gene product.
• a gene product can be a RNA or a polypeptide; untranslated RNA gene products can include structural, catalytic and regulatory RNA molecules. Examples of untranslated RNA gene products include, but are not limited to, tRNA, rRNA, antisense RNAs and ribozymes.
• a coding sequence comprises a gene, which can encode a virulence factor, a resistance factor, or a gene product whose function is essential for a cell under a particular set of environmental conditions. Any gene of interest can be placed in operative linkage with rfl/regulatory region sequences, so that its expression is regulated by the rfl/regulatory region sequences.
• the invention provides recombinant constructs capable of regulating the expression of coding sequences in a host cell. These constructs comprise one or more rfl/regulatory sequences in operative linkage with a coding sequence.
• the constructs are suitable for use in any cell in which raf operon regulatory sequences are functional. Since the rfl/regulatory proteins RafR and RafS can be introduced into a cell along with, or as part of the above- mentioned recombinant construct, regulation of a coding sequence by a raf regulatory sequence will be attainable in many cells, which can include both Gram-positive and Gram-negative microorganisms.
• the host cell is a Gram-positive microorganism, such as, for example, Streptococci, Staphylococci, Enterococci, and Lactococci.
• Preferred species include, for example, S. pneumoniae, S. pyogenes, S. agalactiae, Lancefield group A streptococci, Lancefield group B streptococci, Lancefield group C streptococci, Lancefield group F streptococci, Lancefield group G streptococci, and viridans streptococci.
• Preferred non-streptococcal species in which the rfl/regulatory system can be utilized for regulated expression of coding sequences include, for example, enterococci such as E.
• the recombinant construct is introduced into a host cell to provide regulated expression of a coding sequence.
• constructs into a host cell are performed by methods that are well-known to those of skill in the art, including, for example, natural or artificial transformation, transduction, conjugation, microinjection, transfection, electroporation, CaPO co-precipitation, DEAE-dextran, lipid-mediated transfer, particle bombardment, etc.
• Host cells are cultured in any suitable growth medium, including liquid or solid media.
• Appropriate growth media for various types of microorganisms are well-know to those of skill in the art. See, for example, Bergey's Manual of Systematic Bacteriology, vol. 2, Williams & Wilkins, Baltimore, 1980; Gerhardt et al. "Methods for General and Molecular Microbiology,” American Society for Microbiology, Washington, D.C., 1994; and Murray et al, supra.
• Modulator substances can be added to the growth medium to influence the transcriptional activity of rfl/regulatory sequences. Such effects will be manifested as changes in the expression level of a coding sequence to which the rfl/regulatory sequences are operatively linked.
• the modulator substances can be generally characterized as inducers, which increase transcriptional activity, or negative modulators, which decrease transcription.
• a modulator substance is a metabolite; in a preferred embodiment, it is a carbon source, in a more preferred embodiment, it is a sugar and, in a particularly preferred embodiment, raffmose serves as an inducer and maltose as a negative modulator.
• the present invention utilizes systems which provide low basal expression levels and a high degree of induction. Such methods and compositions can be used, for example, to identify compounds which inhibit the growth of a microorganism, and for discovery of drug targets, including genes involved in virulence and drug resistance. Because the S. pneumoniae rfl/regulatory system is characterized by an induction level of at least 1 ,000-fold over a low basal expression level (see Example 14), it is well-suited for use in the practice of the invention. Accordingly, rfl/regulatory sequences can be used to identify an essential gene of a microorganism, to regulate the level of expression of an essential gene,
• rfl/regulatory sequences such as P rajR , P ra f E , P AGA or others
• Essential genes can include those which are essential for the growth of S. pneumoniae, or those which are essential for the growth of any other microorganism. The essentiality of a gene may depend on the in vivo or in vitro environment of the cell in which it is expressed.
• Example 7 shows the construction and properties of a fusion between the S. pneumoniae ⁇ -galactosidase promoter (P AG A) and the S. pneumoniae leader peptidase (spi) gene.
• P AG A S. pneumoniae ⁇ -galactosidase promoter
• spi S. pneumoniae leader peptidase
• rhamnose utilization regulated by the rhaS or rhaR gene products
• melibiose utilization regulated by the melR gene product
• xylose utilization regulated by the xylR gene product
• jr hydroxyphenylacetic acid utilization regulated by the hpaA gene product
• urease production regulated by the ureR gene product.
• lac which is regulated by lactose and glucose
• trp which is regulated by tryptophan
• tac which is regulated by lactose
• tet which is regulated by tetracycline and tetracycline analogues
• gal which is regulated by galactose
• T7 which is regulated by provision of T7 RNA polymerase
• T3 which is regulated by provision of T3 RNA polymerase
• SP6 which is regulated by provision of SP6 RNA polymerase
• ⁇ p R which is regulated by ⁇ repressor (the cl gene product)
• ⁇ p L which is regulated by ⁇ repressor (the cl gene product).
• regulatability and can be useful in the practice of the invention include, but are not limited to, Ipp, phoA, recA, proU, cst-1, tetA, cadA, nar, Ipp-lac, cspA, Tl-lac, pL-T7, T3-/flc, T5-/flc, nprM-lac, VHb, promoters regulated by two-component regulatory systems, and promoters regulated by the araC/XylS family of regulators.
• Two-component systems include those which utilize protein phosphorylation as a mechanism of signal transduction.
• a sensor protein is phosphorylated upon receipt, by the cell, of an environmental stimulus.
• the phosphate group is then transferred to a regulator protein that undergoes a phosphorylation-induced conformational change which elicits a response such as, for example, gene transcription.
• a regulator protein that undergoes a phosphorylation-induced conformational change which elicits a response such as, for example, gene transcription.
• Additional promoters from Gram-positive organisms which can be tested for their degree of regulatability and can be useful in the practice of the invention include, but are not limited to, spac-1, xylA, lac A, lacR, PI 5, dnaJ, sodA, prtP, prtM, PA170, trpE, nisA, nisF malX, malM, xyl, and bacteriophage promoters from ⁇ rlt and ⁇ 31. See, for example, de Vos et al, supra. Although some of these promoters are not capable, using current techniques, of basal expression levels as low as those that can be obtained with V BAD , they will find use in less-preferred embodiments of the invention.
• fusion of a heterologous regulatory element to a gene encoding an essential cellular function is accomplished by insertion of an ara regulatory cassette into the chromosome of the organism under study, or insertion of an ara regulatory cassette into a plasmid resident in the organism under study.
• the flrfl regulatory cassette can include a DNA molecule containing, in the following order, the Ar ⁇ C gene, Vc (the Ar ⁇ C promoter) and V BAD (the promoter regulating expression of the ArflB, ara A, and flrflD genes). This is the order in which these elements are arranged on the E. coli and S. typhimurium chromosomes, in which the c and V BAD promoters are
• V BAD which is regulated by AraC.
• a cassette containing only V BAD can be inserted, if AraC function is already provided by the cell.
• a cassette containing a gene or nucleotide sequence of interest can be inserted into the chromosome adjacent to V BAD such that the gene or sequence comes under the transcriptional control of V BAD - See Example 13.
• V BAD or any other regulatory element
• a gene or nucleotide sequence of interest can itself be moved to any one of a number of different chromosomal or extrachromosomal locations, using techniques that are well- known in the art.
• fusions can be obtained by random insertion of an flrfl regulatory cassette into a chromosome or a plasmid of a microorganism, followed by screening for strains dependent on arabinose for growth.
• Arabinose-dependent strains will be those in which sequences encoding an essential cellular function have been fused to the flrfl regulatory cassette in such a way that the coding sequences have come under V BAD control.
• a coding sequence can encode a full- length gene product (i.e., the length normally found in the wild-type cell) or any fragment of a gene product capable of encoding an essential cellular function.
• a gene product can be a RNA or a polypeptide; untranslated RNA gene products can include structural, catalytic and regulatory RNA molecules.
• Transposons are DNA segments which have the ability to insert randomly within the a chromosome or plasmid of a host organism. Very little homology is required between the ends of a transposon and its integration site and the process is independent of the host's homologous recombination system. Transposon insertion is typically monitored by selection for an antibiotic resistance marker carried on the transposon. Because transposons can have low site specificity, they are widely used for random inactivation by gene disruption.
• Targeted integration typically involves a recombination event between the chromosome and a conditionally replication-defective plasmid containing chromosomal sequences and an antibiotic resistance marker. Under conditions that are non-permissive for plasmid replication, and in the presence of selective agent, the majority of surviving cells are those in which targeted recombination has occurred between the homologous sequences in the plasmid and the chromosomal DNA.
• Plasmid 35:1-13 Plasmid 35:1-13. The same considerations apply to targeted insertion within a plasmid.
• one method for generating a fusion of an flrfl regulatory cassette to a cellular coding sequence is by flanking the regulatory cassette with sequences homologous to the targeted coding sequence, as described in Example 1 , infra; however, other methods for generating gene fusions will be known to those of skill in the art. See, for example, Casadaban et al. Meth. Enzymology, vol. 100 (ed. R. Wu, L. Grossman, K. Moldave) Academic Press, New York, 1983) pp. 293-308; Silhavy et al, supra; and Gerhardt et al, supra.
• Additional embodiments of the invention include extrachromosomal gene fusions residing, for example, on plasmids.
• plasmid fusions can be constructed in vivo or in vitro, using techniques of genetics and recombinant DNA which are well-known to those of skill in the art. See, for example, Sambrook et al, supra; Ausubel, et al, supra; Silhavy et al, supra; and Gerhardt et al, supra.
• nucleic acids constructed in vitro can be introduced into cells by methods that are well-known in the art, including transformation with naked DNA, electroporation, micro injection, calcium phosphate-mediated transfer, DEAE-dextran-mediated transfer, gene gun, etc., to generate transformed cells. It is clear that methods similar to those described above for ara regulatory cassettes can also be applied to the construction and integration of regulatory
• expression of an essential gene is regulated to a low basal level.
• a low basal level is less than 50% of wild-type, preferably, less than 30%, more preferably, less than 20%, and, most preferably, less than 10%.
• expression of an essential gene at a low basal level will render a cell non-viable; in other cases, it will render a cell hypersusceptible to a biologically-active agent.
• An example of, low, basal-level regulation by flrfl V BAD is provided by Guzman et al, supra. Regulation of cell growth by arabinose, in a strain containing a VsAD-murA fusion, is demonstrated in Example 2, infra.
• Regulation is accomplished by fusion of a target gene to a heterologous regulatory element whose expression can be exogenously controlled, for example, by environmental conditions such as chemicals, nutrients, temperature, pH, osmolarity, etc.
• regulation is such that the level of the target gene product is proportional to the concentration or level of the environmental agent that is used for regulation.
• a target gene is fused to V BAD and regulation is achieved by adjusting the concentration of L-arabinose in the growth medium. Low levels of expression are correlated with low concentrations of arabinose and/or the presence of glucose in the medium.
• regulation is achieved by varying the concentration of an inducer other than arabinose.
• regulation by maltose is achieved, in cells expressing MalR function, when a target gene is fused to mal Pm or mal Px.
• fusion of a target gene to the rfl/regulatory element P AGA allows regulation by raffmose in a cell expressing RafR function.
• Additional regulatory elements in the rfl/regulatory system include the promoter of the rafR gene, P ra fR, and the promoter of the rafE gene, P ra f £ -
• any regulatable promoter whether positively or negatively regulated, can be used to control the expression of a target gene in response to a substance or environmental condition that regulates that particular promoter.
• mutation or "knockout" of one of the two copies of a target gene may lower expression of the target sufficiently for newly-acquired degrees of drug sensitivity to be obtained.
• mutation or "knockout" of one copy of a target gene, coupled with controlled expression of the remaining wild-type copy may be used to achieve heightened drug sensitivity in a diploid.
• situations may be encountered, in both prokaryotes and eukaryotes, in which multiple copies of a gene are present (e.g., ribosomal genes in E. coli). In these situations, knockout and/or inactivation of all but one copy of the gene will allow regulation of that remaining functional copy according to the methods of the invention.
• the methods and compositions of the present invention allow one to control the susceptibility of a cell to a test compound by controlling the amount of a gene product (the target) that is expressed in the cell. This is achieved by adjusting the concentration of an inducer, which will, in turn, regulate the expression of a coding sequence that is fused to a heterologous regulatory element. Sensitivity to a test compound is then determined at various levels of expression of the coding sequence and at different concentrations of the test compound. Expression of lower-than-normal levels of the target will cause a cell to become hyper-susceptible to a compound which interacts with that particular target.
• a cell expressing lower-than-normal levels of a particular gene product may become susceptible to a compound to which it is not normally susceptible (i.e., to which the cell is not susceptible when it is expressing normal levels of the target).
• a compound is a candidate therapeutic which, following chemical modification, may become capable of inhibiting the viability
• the figure depicts the relationship between inducer concentration and the minimum inhibitory concentration (MIC) of a test compound.
• the MIC is determined by assessing the minimal concentration of test compound that will inhibit growth, in the presence of a specified concentration of inducer (if applicable), typically using serial two-fold dilutions of test compound. Growth can be recorded, for example, by spectrophotometry or visual inspection of cultures. The minimum amount of test compound that completely inhibits growth, or supports less than 10% growth compared to a control culture, is defined as the MIC.
• the MIC is constant at all concentrations of inducing agent, because the expression level of the target is not expected to
• inducer concentrations For a cell in which target expression is regulated by inducer concentration, there will be a range of inducer concentrations at which MIC is directly proportional to inducer concentration. Thus, lower inducer concentrations, which result in expression of target at levels lower than wild-type, will be correlated with lower MICs than those observed with wild-type cells. Since this assay relies solely on control of target levels, it provides a screen for candidate therapeutics regardless of whether the function of the target is known.
• Example 3, infra shows that, for cells in which MurA expression is regulated by arabinose, MIC values both below and above the MIC for wild-type cells can be obtained, when cells are challenged with fosfomycin, a MurA inhibitor.
• a target can be part of a multimeric structure composed of different subunits (e.g., a heteromultimer), and a test compound can interact with a sub-region of the multimer contributed by more than one of the subunits, one of which is the target.
• a certain range of inducer concentrations at which MIC is proportional to inducer concentration.
• the target is the limiting component of the multimeric structure.
• the relationship between MIC and inducer concentration reaches a plateau value, which is independent of the MIC for the wild-type strain. This situation is shown schematically in Figure 5.
• Prior art screening methods are not applicable to situations in which a particular compound has multiple targets within a cell, with each target having a different degree of sensitivity to the compound. In these cases, methods of the prior art would detect effects only on the target that is most easily inhibited under the assay conditions.
• the methods of the present invention can be used to control the expression of a target of an inhibitor. If the target is the only cellular gene product that is targeted by the inhibitor, increasing levels of expression of the target will result in higher MICs for the inhibitor (see Figure 4). If the inhibitor
• FIG. 31 has additional targets, increase of MIC as a function of inducer concentration (i.e., target levels) will reach a plateau value, indicating inhibition of a second target by the inhibitor.
• Figure 5 shows an idealized depiction of the data that would be obtained in such a situation. Fixing expression of the first (most sensitive) gene product, while varying expression of the other gene product(s), will allow detection of additional targets.
• a test compound interacts with a single target, the relationship between MIC and inducer concentration will be proportional at all inducer concentrations that are consistent with cell growth. See Examples 3, 4 and 8-13, infra.
• a test compound interacts with multiple targets, or with a structure formed by multiple molecules, one of which is the target, the relationship between MIC and inducer concentration will reach a plateau value at inducer concentrations at and above which the target is no longer the limiting component.
• Targets can be polypeptides and/or nucleic acids. For example, ribosomes contain both types of target.
• Cells can be exposed to any compound that is known in the art or to be synthesized, and the route of exposure can be, for example, by inclusion of the compound in a liquid cell culture medium, by incorporation of the compound into a solid culture medium, or by application of the compound to a solid culture medium, for example, by application to the medium of a porous disc that is saturated with the compound, or by simply pipetting droplets of the compound onto a solid medium.
• Example 1 Construction of a strain containing a fusion of V BAD to murA
• the murA gene was selected for testing because it encodes a cytoplasmic protein that is the target of the drug fosfomycin.
• An E. coli strain carrying a single functional copy of the murA gene under arabinose control in the chromosome was constructed. In this strain, the level of expression of murA is controlled by the amount of arabinose present in the medium. In addition, this strain is dependent on arabinose because this sugar is required to induce the expression of the essential gene murA, and this strain cannot metabolize arabinose because the catabolic genes have been deleted ( ⁇ (araCBA )araD).
• the susceptibility of the strain to fosfomycin was tested at different concentrations of arabinose.
• Susceptibility to unrelated antibiotics that inhibit other targets i.e., tetracycline (a protein synthesis inhibitor) and ciprofloxacin (a DNA gyrase inhibitor) was also investigated.
• a new inhibitor of MurA was identified by the practice of the invention. See Example 5.
• E. coli strains used for this example are E. coli VECO2042 (pir + , recA), E. coli VECO2054 ( ⁇ (araCBA)araD) and E. coli VECO2055 (( ⁇ (araCBA)araD) PmurA : :Km-araC-V B AD)-
• VECO2055 was constructed as follows: Allele replacement requires a double recombination event to occur. Two regions of homology used for recombination were the murA coding region and 400 base pairs of DNA immediately upstream of murA. The chromosomal replacement cassette and the strategy used to replace wild type murA with V BAD - murA is diagrammed in Figure 6. A DNA sequence containing murA was PCR-amplified from E. coli strain
• upstream murA sequence 400 base pairs was PCR amplified from E. coli strain JM109 chromosomal DNA using oligonucleotides DYV-057 (SEQ ID NO. 5, Table 2) and DYV-058 (SEQ ID NO. 6, Table 2), and directly cloned into pCR2.1 (Invitrogen Corporation, Carlsbad, CA).
• the suicide vector pWM95 (Metcalf et al (1996) Plasmid 35:1-13) was chosen to perform the allele replacement procedure.
• pWM95 is an ampicillin- resistant, conditionally replicative plasmid requiring the pir gene in trans for plasmid replication to occur.
• pWM95 also carries the sacB gene which confers sucrose sensitivity to transformed strains grown in the presence of sucrose. When this plasmid is introduced into a host that does not supply the Pir protein, strains carrying chromosomal integrants can be selected. The sacB gene then allows for selecting plasmid-free segregants as sucrose-resistant clones.
• E. coli strain VECO2042 (pir + , recA) was used for all cloning steps with the conditionally replicative pWM95 and its derivatives.
• the araC-V BAD -murA and upstream mur sequences were cloned into the suicide vector pWM95 by three-way ligation to create pDY-10.
• the kanamycin resistance gene from plasmid pBSL99 (ATCC 87141) was cloned as a Hindlll fragment into pDYlO to create pDYl 1.
• pDYl 1 was introduced into E. coli strain VECO2054. Transformants were plated on LB plates supplemented with kanamycin (25 ⁇ g/ml) and ampicillin (100 ⁇ g/ml) and incubated at 37°C overnight.
• V BAD - ⁇ U ⁇ A fusion strain E. coli VECO2055
• Figure 7 shows that growth of the fusion strain is dependent on arabinose concentration, demonstrating the regulation of murA by a heterologous regulatory element and indicating that, at low arabinose concentrations, murA function is limiting for cell growth.
• VECO2055 V ⁇ AD -murA fusion strain
• VECO2054 V ⁇ AD -murA fusion strain
• Fosfomycin is an antibiotic which targets the murA gene product.
• 35 cell pellet was suspended in 1 ml of LB with no added arabinose.
• the cell suspension was diluted 1 : 1000 in LB and used as inoculum.
• inoculum 50 ⁇ l of inoculum, (i.e., diluted cell suspension) was added to each well. After 20 hours of incubation at 35°C, cell growth was measured in each well and compared to wells with no inoculum.
• V BAD -mu A fusion strain E. coli VECO2055
• E. coli VECO2055 to compare its susceptibility to fosfomycin with its susceptibility to several other antibiotics (tetracycline and ciprofloxacin) which do not target the murA gene product.
• Checkerboard assays were performed in 96-well microtiter plates, in which arabinose concentration was varied in the first dimension and antibiotic concentration was varied in the second dimension. Antibiotic concentrations varied by two-fold between rows; dilutions were performed in LB supplemented with different concentrations of arabinose or lacking arabinose. A control row lacking antibiotic, and a control column lacking arabinose, were also included. Total volume in each well was 50 ⁇ l. Similar assays were conducted, using fosfomycin, tetracycline or ciprofloxacin, to test the influence of arabinose on susceptibility to these antibiotics.
• Figure 9 shows that the susceptibility of strain VECO2055 to tetracycline and ciprofloxacin was independent of the presence of arabinose in the medium. The variation observed for sensitivity to ciprofloxacin and tetracycline is typical of that obtained in a MIC determination. Sensitivity to fosfomycin was dependent on arabinose concentration, confirming the results shown in Figure 8. The minimum concentration of arabinose needed to support growth was 5 x 10 "5 %.
• the susceptibility of strain VECO2055 to fosfomycin was strongly associated with the amount of arabinose present in the medium. MICs comparable to the wild type were achievable when sufficient arabinose was added to the medium. Cells became more susceptible to fosfomycin at lower concentrations, in a concentration-dependent manner. The difference in susceptibility between the lowest and highest MICs was approximately 100-fold. The susceptibility to tetracycline and ciprofloxacin remained constant and was independent of arabinose concentration.
• Microtiter plates were used for screening. Wells contained LB with 0, 0.0004, or 0.002% arabinose. Eighty unrelated compounds were tested; test compounds were added to the wells at final concentrations of 2, 4 and 8 ⁇ g/ml. 50 ⁇ l of inoculum was added to each well and the plates were incubated at 35°C. Growth was measured after 24 and 40 hours. The growth of cells incubated at the higher arabinose concentration (0.002%) was not inhibited by any of the test compounds. When cells were incubated at the lower arabinose concentration (0.0004%), compound 47-7-70 was the only test compound that inhibited growth at all three concentrations tested. As a control, the MIC for fosfomycin was determined at each arabinose concentration. Inhibition of MurA activity
• the enzymatic activity of purified MurA was assayed in the presence of the same test compounds used in the screen described supra. Different concentrations of the test compounds were added to buffer (50 mM Tris-HCl, pH 8; 0.2 mM UDP-N-acetylglucosamine) containing 7 ⁇ g/ml MurA. The reaction was started by addition of phosphoenolpyruvate to 0.1 mM, and the reaction mixture was incubated for 30 min at 25°C. Released phosphate was measured with malachite green reagent, and quantitated by spectrophotometry. Only compound 47-7-70 showed inhibitory activity, with an IC 50 of 8 ⁇ g/ml. Susceptibility of VECO2055 to compound 47-7-70 as a function of arabinose concentration
• a checkerboard assay was performed in a 96-well microtiter plate, similar to that described in Example 3, supra. Concentration of compound 47-7-70 was varied in one dimension, and arabinose concentration was varied in the other dimension. A control row lacking compound 47-7-70, and a control column
• VECO2055 inoculum 50 ⁇ l of VECO2055 inoculum, prepared as described in Example 3, supra, was added to each well. The plates were incubated 20 hours at 35°C, at which time cell growth was measured and compared to that in wells that had not received an inoculum. The results are presented in Table 3. As can be seen, increasing susceptibility of VECO2055 to compound 47-7-70 was correlated with lower concentrations of arabinose in the medium, as expected for a compound that blocks cell growth by inhibition of the MurA enzyme.
• Example 6 Construction and properties of a tightly regulated maltose regulatory system
• MalR is a repressor that controls the expression of the maltosaccharide regulon in S. pneumoniae and belongs to the LacI-GalR family of repressors. Two operons are regulated in opposite direction, malXCD (Px promoter) and malMP (Pm promoter), see Figure 1 (SEQ ID NO: 1). Affinity of the MalR for Pm is higher than for Px and, in both cases, a high basal level of expression has been reported. Nieto et ⁇ /. (1997) J. Biol. Chem. 272:30860-30865. This example shows that tighter regulation of the Px promoter can be obtained by modifying the repressor site and by growing cells in minimal medium.
• the S. pneumoniae strains used for this example are S pneumoniae
• Px was PCR amplified from VSPN3026 using oligonucleotides MALI and MAL2 (Table 4), and cloned into the T-tailed PinPoint Xa-1 T- Vector (Promega Corporation, Madison, WI).
• the construct was digested with EcoRI and BamHI, and the 387 bp x-containing fragment was cloned into pR326 vector to create pR326MX.
• the reporter gene used for measuring expression was the gene for catalase, katA, from B. subtilis ATCC 6633.
• telomere sequence was PCR- amplified using oligonucleotides KATl and KAT2 (Table 4) and cloned into the Ndel site of pR326MX to create pR326MXK.
• An additional DNA sequence was added to the construct to target the insertion into a non-essential DNA sequence of the S. pneumoniae chromosome.
• a 300 bp fragment of the cpbA gene was PCR-amplified from the DNA of S. pneumonia VSPN3026, using oligonucleotides CPB1 and CPB2 (Table 4), and the amplification product was inserted into the Clal site of pR326MXK to create pR326MXKC.
• This plasmid was used to transform VSPN3026 and construct a S. pneumoniae strain, VSPN3021, that carries the insertion in the chromosome, according to the insertional duplication mutagenesis method of Claverys et al (1995) Gene 164:123-128.
• a DNA sequence containing the repressor binding site of was mutagenized, to convert a GGA to a GCG (see Figure 1), by using the QuickChange site directed mutagenesis kit (Stratagene, La Jolla, CA).
• the oligonucleotides MAL6 and MAL6C (Table 4) were used as primers, and pR326MXKC was used as template. Note that MAL6C includes the mutant sequence.
• the resultant plasmid, with a mutation in Px, was called pR326MMXKC. This plasmid was used to transform VSPN3026 and construct a S. pneumoniae strain, VSPN3025, that carries the insertion in the chromosome.
• the Px and Pm regulatory region was PCR amplified from VSPN3026 using oligonucleotides MAL3 and MAL2 (Table 4), and cloned into the T-tailed PinPoint Xa-1 T- Vector (Promega Corporation, Madison, WI).
• the construct was digested with EcoRI and BamHI, and the Px and Pm-containing fragment was cloned into the pR326 vector to create pR326MXM.
• the catalase gene was inserted under the control of this regulatory region as described above to create pR326MXMKC. This plasmid was used to transform VSPN3026 and construct a S pneumoniae strain, VSPN3022, that carries the insertion in the chromosome.
• Catalase activity was measured in cell cultures grown in medium C+Y without glucose (Tomasz (1970) J Bacteriol. 101:860-871.) and minimal medium CDEN without glucose. Rane et al. (1940) J. Bacteriol. 40:695-704. Cells were collected in mid-logarithmic phase, centrifuged, and resuspended in 20 mM Tris- HCl buffer, pH 8, containing 0.25% Triton-XlOO. After autolysis of cells, 10 ⁇ l of extract were added to 1 ml of 1.5 mM H 2 O 2 , and the reaction was followed fluorometrically with scopoletin. One unit of catalase activity is 1 ⁇ mol H O 2 hydrolysis per min. at 22°C (see Table 5).
• the data (expressed as units of catalase activity) show that tighter regulation of the maltose regulatory system can be obtained when using minimal medium (CDEN), and that the tightest regulation is obtained when using the modified Px promoter (VSPN3025).
• Example 7 Raffinose-regulated expression of the 5. pneumoniae spi gene by the S. pneumoniae aga promoter
• a DNA sequence containing S. pneumoniae rafR and P AGA was PCR-amplified from S. pneumoniae VSPN3026 chromosomal DNA using oligonucleotides REGAGAEI5' (SEQ ID NO. 20, Table 6) and REGAGANB3' (SEQ ID NO. 21, Table 6) and cloned as an EcoRI/Ndel fragment into the integration vector pR326 (Claverys, et al, supra) to generate plasmid pR326RafRPaga.
• pneumoniae R6 chromosomal DNA was PCR- amplified using oligonucleotides MALSPI5' (SEQ ID NO. 22, Table 6) and MALSPI3' (SEQ ID NO. 23, Table 6) and cloned as an Ndel/BamHI fragment into plasmid pR326RafRPaga, resulting in plasmid pR326RPASPI.
• VSPN3041 The site of insertion was verified in one of the isolates, S. pneumoniae strain VSPN3041. Insertion in the targeted site in the spi gene was verified by PCR using the primers PagalOO (SEQ ID NO. 25, Table 6) and Spi3'SPn (SEQ ID NO. 26, Table 6). This analysis indicated that VSPN 3041 carried a truncated 270 bp spi gene under natural promoter control and a complete spi gene under P AGA control.
• Table 6 Sequences of oligonucleotides used for construction of a P AGA -S/M fusion and targeting of the fusion to the chromosomal spi gene
• VSPN3041 and VSPN3026 were grown for 4 hours at 37° C in 5 ml C+Y+raf. Ten microliters of the culture was added to 10 ml C+Y containing 1% sucrose, incubated for 6 hours at 37° C, then frozen as a 15% glycerol solution. A 1 :10 dilution of the frozen stock in C+Y lacking sucrose, containing 2 x 10 6 colony forming units/ml, was used as inoculum.
• Figure 10 shows the growth of VSPN3041 at different raffinose concentrations, measured by optical density. It is clear that growth of the fusion strain is dependent on raffinose concentration, demonstrating that an essential gene is regulated by raffinose in VSPN3041. In the experiment shown in Figure 11, the growth of VSPN3041 on raffinose is compared to growth on sucrose (each sugar present in medium at 0.2% w/v).
• the raffinose-dependent phenotype of VSPN3041, compared to its parent strain, indicates that P AGA controls the expression of an essential gene in VSPN3041.
• the essential raffinose- regulated gene in VSPN3041 is the spi gene (or a gene downstream of spi).
• the spi gene (or its downstream gene) in VSPN3041, regulated by the P AGA promoter in response to raffinose is limiting for cell growth at low raffinose concentrations. Since growth is dependent on the expression of this essential gene and the level of induction can be controlled, the growth of VSPN3041 can be controlled by the induction or repression of the P AGA promoter.
• Example 8 Construction and properties of a strain containing a J* BAD - def transcriptional fusion
• a Construction of V BAP -def transcriptional fusions in E. coli The product of the def gene, the enzyme peptidyl deformylase, plays a major role in protein synthesis in bacteria.
• a DNA sequence containing the full- length def gene was PCR-amplified from chromosomal DNA of E. coli strain JM109 using oligonucleotides DYV-157 (SEQ ID NO: 27) and DYV-158 (SEQ ID NO: 28), and cloned as a Ncol/Bglll fragment into expression vector pBAD- MycHisB (Invitrogen Corporation, Carlsbad, CA), to create pDY8. Oligonucleotide sequences are given in Table 7.
• pDY20 was created by PCR-amplification of the kanamycin resistance cassette from plasmid pBSL99 with the primers DYV-087 (SEQ ID NO: 35) and DYV-088 (SEQ ID NO: 36) and cloned into pBlueScriptSKII " (Stratagene, La Jolla, CA) as an Xba/Sacl fragment. 600 base pairs of upstream fle/sequence were PCR amplified from E.
• coli strain JM109 chromosomal DNA using oligonucleotides DYV-155 (SEQ ID NO: 29) and DYV-156 (SEQ ID NO: 30), and cloned as a Sacl/Ascl fragment into vector pDY20 to create pDY9. Oligonucleotide sequences are given in Table 7.
• the suicide vector pKO3 (Link et al, supra) was chosen to perform the allele replacement procedure with the def gene.
• pKO3 is a chloramphenicol- resistant vector containing the temperature-sensitive pSClOl origin of replication and the sacB gene for counter-selection.
• pKO3 -derived plasmids are incapable of autonomous replication at 43°C. When a host strain harboring a pKO3 construct is plated at 43°C on media containing chloramphenicol, chromosomal integrants can be selected. Integration of a pKO3 construct into a host chromosome at
• the araC-V BAD -def cassette was excised as an Ndel/Bglll fragment from pDY8, and the upstream fle/Kanamycin cassette was excised as an Eel 136 II/Ndel fragment from pDY9.
• the purified fragments were cloned in a three-way ligation with Smal/BamHI digested pKO3 to create pDY15.
• pDY15 was introduced into E. coli strain VECO2054. Transformants were selected on LB plates supplemented with chloramphenicol (25 ⁇ g/ml) and kanamycin (25 ⁇ g/ml), incubated at 30°C overnight.
• Sucrose-resistant recombinants were screened for chloramphenicol sensitivity and arabinose-dependent growth. Chromosomal replacement of the def gene in a clone, VECO2065 (araC-V BAD-def), was verified by assaying for specific PCR products, derived from the chromosomal junctions, with PCR primer pairs DYV-069 (SEQ ID NO: 37VDYV-082 (SEQ ID NO: 10) and DYV-073 (SEQ ID NO: 9)/DYV-155 (SEQ ID NO: 29). See Tables 2 and 7 for primer sequences.
• VECO2065 V B AD-def
• VRC483 is a compound with antibacterial activity that targets the def gene product. This compound was identified in a deformylase screen at Versicor and the IC 0 is 11 nM for E. coli deformylase. Deformylase activity was measured as described. Rajagopalan et al (1997) Biochemistry
• VECO2065 The susceptibility of VECO2065 to the unrelated antibiotics fosfomycin and ciprofloxacin was also tested.
• FIG. 13 shows the minimum inhibitory concentration (MIC) of VRC483, as a function of arabinose concentration, for the V BAD -def strain VECO2065.
• the parent wild-type strain (VECO2054) was not susceptible to VRC483 in the range tested.
• VECO2065 was susceptible to VRC483 at low arabinose concentrations, and the susceptibility was inversely related to the inducer concentration. Susceptibility of VECO2065 to compounds that do not target the product of the def gene, such as fosfomycin and ciprofloxacin, did not change with arabinose concentration.
• a Construction of V BAD -f lA transcriptional fusions in E. coli The product of the folA gene is a dihydrofolate reductase. This enzyme is involved in folate synthesis in bacteria.
• a DNA sequence containing the full- length folA gene was PCR-amplified from the chromosomal DNA of E. coli strain JM109, using oligonucleotides DYV-095 (SEQ ID NO: 31) and DYV-096 (SEQ ID NO: 32), and cloned as an Ncol/Bglll fragment into expression vector pBAD- MycHisB (Invitrogen Corporation, Carlsbad, CA), to create pDY5. Oligonucleotide sequences are given in Table 7.
• the araC-V BAD -folA cassette was excised as a Ndel/Bglll fragment from pDY5, and the upstream / ⁇ 4-kanamycin cassette was excised as an Ecll36 II/Ndel fragment from pDY6.
• the purified fragments were cloned in a three-way ligation with Smal/BamHI digested pWM95 to create pDY42.
• pDY42 was introduced into E. coli strain VECO2054. Transformants were selected on LB plates supplemented with ampicillin (100 ⁇ g/ml) and kanamycin (25 ⁇ g/ml), incubated at 37°C overnight.
• VECO2079 V B AD -folA strain to trimethoprim and other antimicrobial agents
• trimethoprim is a compound with antibacterial activity that targets dihydrofolate reductase, the product of the folA gene.
• the susceptibility of VECO2079 to the unrelated antibiotics fosfomycin and ciprofloxacin was also tested. 1. Preparation of inoculum. Cells were grown overnight in 5 ml of LB supplemented with 0.1 % arabinose, on a rotary shaker at 35°C and 200 ⁇ m.
• Figure 14 shows the minimum inhibitory concentration (MIC) of trimethoprim, as a function of arabinose concentration, for the V BAD -folA strain (VECO2079) compared to the parent wild-type strain, VECO2054.
• the results show that the MIC of trimethoprim, afolA inhibitor, was dependent on arabinose concentration in the BAD -folA strain (VECO2079); while MIC values of trimethoprim for the wild-type strain were not dependent on arabinose concentration.
• Figure 14 also shows that susceptibility of VECO2079 to compounds that do not target the product of the fol A gene, such as fosfomycin and ciprofloxacin, did not change with arabinose concentration.
• Example 10 Construction and properties of a strain containing a ⁇ BAD -gyrB transcriptional fusion
• V ⁇ AD -gyrB transcriptional fusions in E. coli The product of the gyrB gene is the beta subunit of gyrase, a bacterial DNA topoisomerase.
• a DNA sequence containing the full-length gyrB gene was PCR-amplified from the chromosomal DNA of E. coli strain JM109, using oligonucleotides DYV-099 (SEQ ID NO: 41) and DYV-204 (SEQ ID NO: 42), and cloned as an Ncol/Pstl fragment into expression vector pBAD-MycHisB (Invitrogen Co ⁇ oration, Carlsbad, CA) to create pDY34. Oligonucleotide sequences are given in Table 7.
• the ⁇ r ⁇ C-V BAD -gyrB cassette was excised as an Ndel/ Xba fragment from pDY34, and the upstream gyrP-kanamycin cassette was excised as an Ecll36 11/ Ndel fragment from pDY38.
• the purified fragments were cloned in a three-way ligation with Smal/Xbal digested pWM95 to create pDY40.
• pDY40 was introduced into E. coli strain VECO2054. Transformants were selected on LB plates supplemented with ampicillin (100 ⁇ g/ml) and
• sucrose-resistant recombinants were screened for ampicillin sensitivity and arabinose-dependent growth.
• VECO2083 V ⁇ AP-gyrB strain to novobiocin and other antimicrobial agents
• VCJ005 CCACCATAATTGACGAACGC 47
• VCJ007 GTCTTCGGTACGGTCATGGTG 48
• This example describes the construction of a strain of E. coli, VECO2068, with an essential gene, def, under V BAP control, and with a deletion in the tolC gene.
• the essential def gene is under V BAP control
• the susceptibility of VECO2068 to inhibitors of the def gene product depends on the concentration of arabinose in the growth medium. Mutants in tolC are hypersusceptible to many compounds, because tolC encodes an outer membrane protein, which can serve as a component of an efflux pump.
• the threshold for susceptibility to compounds which interact with the def gene product is lowered in a tolC mutant, compared to wild-type. Because of its heightened susceptibility, the tolC/ ' ⁇ AP -def strain can be used for detecting compounds that otherwise would not have been identified as inhibitors of a strain that is wild-type for tolC.
• the tolC gene was PCR amplified from E. coli strain VECO1004 using primers VCJ005 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO: 48, Table 7).
• the 2.7 kb PCR product was blunt-end cloned into pUCl 8 creating pCH12.
• a 700 bp internal deletion of tolC was created by digestion of pCH12 with the compatible enzymes Pstl and Nsil, creating pCH13.
• the 2.0 kb AtolC fragment was excised from pCH13 by Smal/Ehel digestion and cloned into Smal digested pKO3 creating pDY92.
• the pDY92 plasmid was used to introduce the tolC deletion mutation (AtolC) into the chromosome of VECO2065 (an E. coli strain containing a chromosomal V ⁇ ⁇ p-def fusion) via the selection /counter-selection procedure previously described for other suicide vector constructs. See Examples 8-10 Transformed cells were screened for successful integration of the AtolC mutation by plating on LB + 0.2% arabinose, and replica-plating onto MacConkey agar, which does not support growth of AtolC mutants. Confirmation of AtolC integration in MacConkey-sensitive clones was verified by PCR with oligonucleotides VCJ005 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO:
• VECO2068 AtolC, V ⁇ Ap-def
• VECO2066 a parent strain containing a deleted tolC gene and lacking the V BAD -def fusion
• VRC483 is a compound with antibacterial activity that targets the def gene product. This compound was identified in a deformylase screen at Versicor and the IC 50 is 11 nM for E. coli deformylase. Deformylase activity was measured as described in Example 8 (Rajagopalan et al, supra).
• Figure 16 shows the minimum inhibitory concentration (MIC) of VRC483, as a function of arabinose concentration, for the tolC/V BAD -def strain VECO2068.
• the results show that the MIC of VRC483, a deformylase inhibitor, for VECO2068 is dependent on the concentration of arabinose in the growth
• Example 12 Construction and properties of a S. pneumoniae strain containing a P AGA -def transcriptional fusion A. Construction of P AGA -def transcriptional fusions in S. pneumoniae
• a DNA sequence containing rafR and P AGA was PCR- amplified from S pneumoniae VSPN3026 chromosomal DNA using oligonucleotides REGAGAEI5' (SEQ ID NO: 20, Table 6) and REGAGANB3' (SEQ ID NO: 21, Table 6) and cloned as an EcoRI/Ndel fragment into the integration vector pR326 (Claverys et al, supra), resulting in plasmid pR326RafRPaga.
• the first 317 bp of the deformylase gene (def) from S. pneumoniae VSPN3026 chromosomal DNA were PCR amplified using oligonucleotides MALDEF5' (SEQ ID NO: 49 Table 8) and MALDEF3' (SEQ ID NO: 50 Table 8) and cloned as an Ndel/BamHI fragment into plasmid pR326RafRPaga, resulting in plasmid pR326RPADEF.
• pR326RPADEF a DNA sequence containing only P AGA and the def fragment was amplified using oligonucleotides Paga5'EI (SEQ ID NO: 24, Table 6) and MALDEF3' (SEQ ID NO: 50, Table 8) and cloned into the T-tailed pGEM-T Easy Vector (Promega Co ⁇ oration, Madison, WI).
• the construct was digested with EcoRI and the P AGA-def containing fragment was cloned into the integration vector pR326 to create pR326Pagadef.
• This plasmid was used to transform VSPN3026, grown in C+Y without sucrose and supplemented with different raffinose concentrations (two-fold dilutions from 2% to 0.008 %). Transformants were used to inoculate tubes containing 2 ml C+Y medium supplemented with chloramphenicol (2.5 ⁇ g/ml) and different raffinose
• the plates were incubated overnight at 35°C and a single colony was picked and transferred to C+Y medium supplemented with chloramphenicol (2.5 ⁇ g/ml) and raffinose (0.03%).
• the resulting S. pneumoniae strain, VSPN3044 carries an insertion at the fl * e/locus in the chromosome, which was verified by PCR using the primers PagalOO (SEQ ID NO: 25, Table 6) and DEF3'Bam (SEQ ID NO: 51, Table 8).
• the strain carries a truncated 316 bp def gene under natural promoter control and a full-length def gene under P AGA control.
• MALDEF3' CCGCGGATCCAAATCGTAGGCTTCCTGTGG 50
• VRC483 is a compound with antibacterial activity that targets the def gene product. This compound was identified in a deformylase screen at Versicor and the IC 50 is 11 nM for E. coli deformylase. Deformylase activity was measured as described in
• VSPN3044 and VSPN3026 were grown for 4 hours at 37°C in 5 ml C+Y lacking sucrose and supplemented with 0.03 % raffinose. Cells were grown to an OD of 0.2 at 600 nm. Aliquots of 200 ⁇ l were frozen at -70°C as a 15% glycerol solution. When needed for inoculation, frozen stock was melted, centrifuged, and the supernatant discarded. The cell pellet was resuspended in 1 ml of C+Y with glucose, diluted 1 : 1000 into the same medium (chloramphenicol was added to the VSPN3044 medium) and used as inoculum.
• Figure 17 shows the minimum inhibitory concentration (MIC) of VRC483, as a function of raffinose concentration, for the P AGA -def strain
• VSPN3044 compared to the parent wild type strain VSPN 3026.
• the results show that, for VSPN3044, the MIC of VRC 483, a deformylase inhibitor, is dependent on the concentration of raffinose in the growth medium. MIC values for the wild-type strain are not dependent on raffinose concentration.
• Figure 17 also shows that the susceptibility of VSPN 3044 to erythromycin and vancomycin, which do not target the def gene, did not vary with raffinose concentration.
• Example 13 Construction and properties of a strain containing a ⁇ BAD -lpxC transcriptional fusion and a tolC deletion This example demonstrates the construction and properties of a fusion in which the gene of interest is inserted downstream of the V BAP promoter at the
• V BAP normal chromosomal location of V BAP . In this way, potential polar effects on genes downstream from the gene of interest are avoided.
• the product of the IpxC gene is the enzyme UDP-3-O-(R-3- hydroxymyristoyl)-N-acetylglucosamine deacetylase, which plays a major role in lipopolysaccharide synthesis in Gram-negative bacteria.
• a DNA sequence containing the full-length IpxC gene was PCR-amplified from E.
• coli strain MG1655 chromosomal DNA using oligonucleotides DYV-240 (SEQ ID NO: 56) and DYV-241 (SEQ ID NO: 57, Table 9), and cloned as an Ncol/Bglll fragment into pNR41 creating pNR43.
• pNR41 contains two regions of homology with the araBAD locus on the chromosome. One region contains an optimized V BAP promoter and approximately 500 bp of upstream DNA corresponding to the araC gene, the second region contains 600 bp of an internal fragment of the araD gene.
• the araC-V BA p-lpy-C-araD cassette was excised from pNR43 as an Xmal/Sall fragment and cloned into Xmal/Sall digested pKO3, thus creating pNR48.
• pNR48 was transformed in E. coli strain MG1655. Transformants were selected on LB plates supplemented with chloramphenicol (25 ⁇ g/ml) at 30°C. A number of transformants were streaked onto LB plates supplemented with chloramphenicol (25 ⁇ g/ml) and incubated at 43 °C overnight. Isolated colonies were then restreaked at 43 °C onto LB plates supplemented with chloramphenicol (25 ⁇ g/ml).
• Plasmid pNR36 was transformed in E. coli strain VECO2520. Transformants were selected on LB plates supplemented with 0.2% arabinose and chloramphenicol (25 ⁇ g/ml) at 30°C. A number of transformants were streaked onto LB plates supplemented with 0.2% arabinose and chloramphenicol (25 ⁇ g/ml) and incubated at 43°C overnight. Isolated colonies were then restreaked at 43°C onto LB plates supplemented with 0.2% arabinose and chloramphenicol (25 ⁇ g/ml). Isolated colonies were next streaked onto LB plates supplemented with 0.2% arabinose and incubated at 37°C overnight.
• VECO2522 Arabidyl-N-V ⁇ AD -lpxC ,AlpxC
• PCR primer pairs DYV-224/DYV-227 SEQ ID NOS: 52 and 55, Table 9.
• the tolC gene was PCR-amplified from E. coli strain VECO1004 using primers VCJ005 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO: 48, Table 7).
• the 2.7 kb PCR product was blunt-end cloned into pUC18 creating pCH12.
• a 700 bp internal deletion of tolC was created by digestion of pCH12 with the compatible enzymes Pstl and Nsil, creating pCH13.
• the 2.0 kb AtolC fragment was excised from pCH13 with Smal-Ehel and cloned into Smal digested pKO3, creating pDY92.
• the AtolC mutation was introduced onto VECO2522 and E. coli MJ1655 with pDY92 via the selection/counter-selection procedure previously described for other suicide vector constructs.
• Successful integration of the AtolC mutation was screened on MacConkey agar which does not support growth of AtolC mutants.
• Confirmation of AtolC integration in MacConkey-sensitive clones was verified by PCR with oligonucleotides VCJ005 (SEQ ID NO: 47, Table 7) and VCJ007 (SEQ ID NO: 48, Table 7).
• VECO2524 is an araC-V BAD -lpxC, AlpxC, AtolC mutant
• VECO2526 is a AtolC mutant.
• V B Susceptibility of VECO2524 (V B AD-lpxQ to L159692 and other antimicrobial agents
• VECO2526 V B AD-lpxQ to L159692 and other antimicrobial agents
• LI 59692 is an antibacterial compound that targets the IpxC gene product. Onishi et al. (1996) Science 274:980-982. The susceptibility of VECO2526 to other unrelated antibiotics, linezolid and erythromycin, was also tested.
• Figure 18 shows the minimum inhibitory concentration (MIC) of LI 59692, linezolid, and erythromycin, as a function of arabinose concentration, for the V ⁇ AD -lpxC strain.
• the susceptibility of the isogenic tolC strain, VECO2526, to any of the compounds tested was not influenced by the amount of inducer in the medium.
• Example 14 Regulatory properties of the S. pneumoniae raf gene cluster
• the aga gene exhibits sequence homology to other prokaryotic ⁇ -galactosidases,
• S. pneumoniae aga gene regulated by its promoter P AGA , serves as a naturally-occurring reporter gene for use in the study of induction and regulation of the S. pneumoniae raf gene cluster, and can also be used as a reporter gene for the analysis of other potential regulatory sequences in S. pneumoniae and other microorganisms.
• S. pneumoniae strain VSPN3026 was used as wild-type for the experiments described herein.
• Cells were grown in C+Y Medium (Tomasz (1970) J Bacteriol 101:860-871) containing 0.2% (w/v) sucrose and 0.2% (w/v)' glucose, and logarithmic phase cells were frozen in 20% (v/v) glycerol, to be used for inoculation.
• C+Y medium containing various sugars was used. All sugars were used at a concentration of 0.2% (w/v). Eight ml of medium was inoculated with 200 ⁇ l of frozen stock cells, and the culture was grown at 37°C.
• Alpha-galactosidase activity was measured in a buffer containing 100 mM sodium phosphate, 1 mM MgCl , 45 mM ⁇ -mercaptoethanol, pH 7.5, containing /7-nitrophenyl- ⁇ -D-galactopyranoside (Sigma Chemical, St. Louis, MO) at a final concentration of 0.9 mg/ml.
• the reaction was initiated by addition of 10 ⁇ l cell lysate to 90 ⁇ l of reaction buffer and the reaction mixture was incubated at 25°C. Enzymatic activity was monitored by measuring absorbance at 405 nm. A 405 measurements were taken every 30 sec for 30 min using a Spectramax 250
• Results are shown in Table 10. As can be seen, low basal levels of ⁇ -galactosidase activity were observed in lysates from cells grown with sugars other than raffinose as a sole carbon source. However, a 200-1 ,000-fold induction of ⁇ -galactosidase activity was observed in cells grown on raffinose. Combinations of raffinose and a second sugar gave enzyme levels that were 16-500-fold greater than those obtained with the second sugar alone. Thus, by adjusting the concentration of sugar and/or the combination of sugars in the medium, expression of coding sequences regulated by rfl/regulatory sequences can be modulated over an approximately 1 ,000-fold range.
• the resulting construct was digested with EcoRI, to release an approximately 339 bp fragment containing aga sequences.
• This fragment was inserted into the EcoRI site of pR 326 (Claverys et al, supra) to create pR326AGAKO.
• This plasmid was used to transform VSPN3026 to construct a S. pneumoniae strain, VSPN3037, with an insertion of pR326 sequence in the chromosomal aga gene, thereby inactivating the flgfl gene.
• a DNA fragment containing an internal portion of the rafR gene was
• the amplified sequence was ligated into pCRII (Invitrogen, Carlsbad, CA). The resulting construct was digested with EcoRI, and an approximately 440 bp r ⁇ /7?-containing fragment was inserted into the EcoRI site of pR 326 to create pR326RAFRKO.
• This plasmid was used to transform VSPN3026 to construct a S. pneumoniae strain, VSPN3038, with an insertion of pR326 sequence in the chromosomal rafR gene, thereby inactivating the rafR gene.
• a DNA fragment containing an internal portion of the ra ⁇ gene was PCR-amplified using oligonucleotides rafSl and rafS2 as primers. See Table 11 for sequences. This generated a 454 bp amplification product, which was ligated into pCRII (Invitrogen, Carlsbad, CA). The resulting construct was digested with EcoRI and an approximately 445 bp r ⁇ /S-containing fragment was obtained, which was inserted into the EcoRI site of pR 326 to create pR 326RAFSKO. This plasmid was used to transform VSPN3026 to construct a S. pneumoniae strain,
• Oligonucleotide Sequence (5' - 3') SEQ ID NO. agal GCTCAACTTAGTCTGACTTTG 60 aga 2 CAAACACATTCCCAGCATCCTCTG 61 rafRl CGCGGATCCTCGAGAAGTTGTCTAGCTCGG 62 rafR 2 CCGGAATTCTAGGAATCACTGGAGGGAAA 63 rafS 1 CCGCGGATCCGCTACAAGTAGTGTGTAGGATGG 64 rafS2 GCCGGAATTCAATCCTACCAAGCTGTCTACC 65
• the flgfl, ra ⁇ and ra ⁇ mutant strains were tested for growth and for ⁇ -galactosidase activity, when provided with raffinose, sucrose or a mixture of raffinose and sucrose as carbon source.
• Mutant strains were grown in C+Y medium containing different carbon sources (as indicated in Table 12) and growth was monitored by absorbance of cultures at 600 nm, measured by spectrophotometry. When cultures reached an A 600 of 0.4, cells were collected and assayed for ⁇ -galactosidase activity as described supra. Assay results are shown in Table 12.
• a strain harboring a mutation in the rafR gene is able to grow on raffinose, but induced levels of ⁇ -galactosidase in this strain are seven-fold lower than in wild-type cells. See Table 12. Thus, ra ⁇ function is required for maximal induction of aga activity. These results are those expected if the rafR gene product acts as an activator of the aga gene, and are consistent with the presence, in the amino acid sequence of the rafR gene product, of the AraC family signature sequence. They are also consistent with the high degree of homology between the RafR amino acid sequence and the sequences of other transcriptional activator proteins.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Biomedical Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Gastroenterology & Hepatology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Plant Pathology (AREA)
• Analytical Chemistry (AREA)
• Immunology (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Applications Claiming Priority (15)

Publications (1)

Family

ID=27568420

Family Applications (1)

Country Status (4)

Families Citing this family (7)

• 1999
  • 1999-04-14 WO PCT/US1999/008164 patent/WO1999052926A1/en not_active Application Discontinuation
  • 1999-04-14 CA CA002325602A patent/CA2325602A1/en not_active Abandoned
  • 1999-04-14 JP JP2000543482A patent/JP2002511239A/ja not_active Withdrawn
  • 1999-04-14 EP EP99917494A patent/EP1071697A1/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events